Kathy Y. Liu
University College London
PsychiatryInternal medicinePsychologyNeuroscienceCognitionIntensive care medicineIn vivoLocus coeruleusDiseaseDementiaPsychosisAntipsychoticPopulationAge relatedAgeingAlzheimer's diseaseClinical trialClinical psychologyMedicineBiology
26Publications
10H-index
401Citations
Publications 25
Newest
#1Kathy Y. Liu (UCL: University College London)H-Index: 10
#2Naaheed Mukadam (UCL: University College London)H-Index: 18
Source
#1Kathy Y. Liu (UCL: University College London)H-Index: 10
#2Lon S. Schneider (SC: University of Southern California)H-Index: 104
Last. Robert Howard (UCL: University College London)H-Index: 89
view all 3 authors...
Deciding on the smallest change in an outcome that constitutes a clinically meaningful treatment effect (ie, the minimum clinically important difference [MCID]) is fundamental to interpreting clinical trial outcomes, making clinical decisions, and designing studies with sufficient statistical power to detect any such effect. There is no consensus on MCIDs for outcomes in Alzheimer's disease trials, but the US Food and Drug Administration's consideration of aducanumab clinical trials data has exp...
Source
#1Kathy Y. Liu (UCL: University College London)H-Index: 10
#2Robert Howard (UCL: University College London)H-Index: 89
Last. Alistair Burns (University of Manchester)H-Index: 98
view all 18 authors...
ABSTRACT Objectives In response to a commissioned research update on dementia during the COVID-19 pandemic, a UK-based working group, comprising dementia researchers from a range of fields and disciplines, aimed to describe the impact of the pandemic on dementia wellbeing and identify priorities for future research Methods We supplemented a rapid literature search (including unpublished, non-peer reviewed and ongoing studies/reports) on dementia wellbeing in the context of COVID-19 with expert g...
Source
#1Kathy Y. Liu (UCL: University College London)H-Index: 10
#2Julio Acosta-Cabronero (UCL Institute of Neurology)H-Index: 29
Last. Robert Howard (UCL: University College London)H-Index: 89
view all 6 authors...
Abstract Sensitive and reliable in vivo imaging of the locus coeruleus (LC) is important to develop and evaluate its potential as a biomarker in neurodegenerative diseases such as Alzheimer’s disease (AD). It is not known whether AD-related alterations in LC integrity can be detected using 18F-labelled fluoro-2-deoxyglucose (FDG) positron emission tomography (PET). Mean FDG-PET images from AD patients (N ​= ​193) and controls (N ​= ​256) from the ADNI database were co-registered to a study-wise ...
Source
#1Kathy Y. Liu (UCL: University College London)H-Index: 10
#2Anya Borissova ('KCL': King's College London)
Last. Robert Howard (UCL: University College London)H-Index: 89
view all 8 authors...
Introduction There is increasing emphasis on the importance of optimizing and standardizing clinical trials of agitation in Alzheimer's disease (AD), but the risks of bias arising from published trials and the number and design of unpublished studies are poorly understood. Methods Using the ClinicalTrials.gov database, we systematically reviewed all registered investigational clinical trials for agitation in AD to describe the landscape of agitation drug treatment trials and to assess their qual...
Source
#1Gill Livingston (UCL: University College London)H-Index: 84
#2Hossein Rostamipour (Camden and Islington NHS Foundation Trust)H-Index: 1
Last. Louise Marston (UCL: University College London)H-Index: 38
view all 9 authors...
Summary Background People living in group situations or with dementia are more vulnerable to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Older people and those with multimorbidity have higher mortality if they become infected than the general population. However, no systematic study exists of COVID-19-related outcomes in older inpatients in psychiatric units, who comprise people from these high-risk groups. We aimed to describe the period prevalence, demographics...
6 CitationsSource
#1Kathy Y. Liu (UCL: University College London)H-Index: 10
#2Suzanne Reeves (UCL: University College London)H-Index: 19
Last. Robert Howard (UCL: University College London)H-Index: 89
view all 7 authors...
There is clinical overlap between presentations of dementia due to limbic-predominant age-related TDP-43 encephalopathy (LATE) and Alzheimer's disease. It has been suggested that the combination of Alzheimer's disease neuropathological change (ADNC) and LATE neuropathological changes (LATE-NC) is associated with greater neuropsychiatric symptom burden, compared to either pathology alone. Longitudinal Neuropsychiatric Inventory and psychotropic medication prescription data from neuropathologicall...
1 CitationsSource
#1Suzanne Reeves (UCL: University College London)H-Index: 19
#2Julie Bertrand (UCL: University College London)H-Index: 13
Last. Robert Howard (UCL: University College London)H-Index: 89
view all 11 authors...
Background In the treatment of psychosis, agitation and aggression in Alzheimers disease (AD), guidelines emphasise the need to use the lowest possible dose of antipsychotic drugs, but provide no information on optimal dosing. Aims This analysis investigated the pharmacokinetic profiles of risperidone and active metabolite, 9-hydroxy (OH)-risperidone, and how this related to emergent extrapyramidal side effects (EPS), using data from The Clinical Antipsychotic Trials of Intervention Effectivenes...
Source
#1Dorothea Hämmerer (UCL: University College London)H-Index: 16
#2Alexandra Hopkins (UCL: University College London)H-Index: 3
Last. Emrah Düzel (UCL: University College London)H-Index: 71
view all 11 authors...
Source
#1Kathy Y. Liu (UCL: University College London)H-Index: 10
#2Julio Acosta-Cabronero (UCL Institute of Neurology)H-Index: 29
Last. Dorothea Hämmerer (Otto-von-Guericke University Magdeburg)H-Index: 1
view all 12 authors...
1 CitationsSource